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Summary
Experimental autoimmune encephalomyelitis (EAE) in the Lewis rat is a self-limited inflammatory
process localized to the central nervous system that is induced by the injection of myelin basic
protein (MBP) in adjuvant . Oral administration of MBP suppresses EAE, and this suppression
is mediated by CD8+ T cells that adoptively transfer protection and suppress both in vitro and
in vivo by the release of transforming growth factor (TGF) (3 after antigen-specific triggering.
Furthermore, oral tolerance to MBP is enhanced by the concomitant oral administration of
lipopolysaccharide (LPS) . The present study was undertaken to determine whether the disease
course in EAE and its suppression by oral tolerization toMBP is associated with distinct patterns
ofcytokine expression in the target organ . Detailed immunohistology of the brain was performed
at the peak of clinical disease (day 14 after immunization) and after recovery (day 18) in control
(ovalbumin [OVA]-fed), MBP-fed, and MBP plus LPS-fed animals . Brains from OVA-fed animals
at the peak of disease showed perivascular infiltration with activated mononuclear cells which
secreted the inflammatory cytokines interleukins (IL) 1, 2, 6, 8, TNF-a, and interferon 'y. The
inhibitory cytokines TGF-0 and IL4, and prostaglandin E2 (PGE2) were absent. In MBP orally
tolerized animals there was a marked reduction of the perivascular infiltrate and downregulation
of all inflammatory cytokines. In addition, there was upregulation of the inhibitory cytokine
TGF-,(3 . In MBP plus LPS orally tolerized animals, in addition to upregulation of TGF-0 and
reduction of inflammatory cytokines, there was enhanced expression of IL-4 and PGE2,
presumably secondary to activation of an additional population of immunoregulatory cells . In
OVA-fed animals that had recovered (day 18), staining for inflammatory cytokines diminished,
and there was the appearance ofTGF-0 and IL-4 . These results suggest that suppression ofEAE,
either induced by oral tolerization or that which occurs during natural recovery is related to
the secretion of inhibitory cytokines or factors that actively suppress the inflammatory process
in the target organ .
Oral administration ofantigens induces a state of immuno-
logic unresponsiveness, termed oral tolerance (1) . We
and others have shown that oral administration of autoan-
tigens suppresses experimental autoimmune diseases including
This work was presented in part in abstract form at the American Academy
of Neurology on 6 May 1992 .
experimental autoimmune encephalomyelitis (EAE)l (2-5),
uveitis (6), collagen- (7) and adjuvant-induced arthritis (8),
and diabetes in the NOD mouse (9) . We have also shown
1 Abbreviations used in this paper. DTH, delayed type hypersensitivity ; EAE,
experimental autoimmune encephalomyelitis ; HPF, high power field ;
ICAM, intercellular adhesion molecule; MS, multiple sclerosis; PCNA,
proliferating cell nuclear antigen; TF, tissue factor ; TM, thrombomodulin .
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splenocytes, and induction of oral tolerancewith polymorphic
class II MHC peptides in the rat (10).
Oral administration of myelin basic protein (MBP) sup-
presses EAE and this suppression is mediated by CD8+ T
cells that adoptively transfer protection and suppress in vitro
proliferative responses when stimulated with the tolerizing
antigen (2). These MBP-specific CD8+ T cells mediate sup-
pression in vitro by the release of TGF-0 after triggering by
MBP (11). Furthermore, administration of anti TGF-a in vivo
abrogates the protective effects of orally administered MBP
(11). Additional studiesfrom our laboratory have shown that
administration of LPS orally in conjunction with MBP en-
hances the protective effect of orally administered MBP on
EAE. This enhanced protection was manifested clinically and
as measured by suppression of delayed-type hypersensitivity
(DTH) responses to MBP. LPS alone or given subcutaneously
with oral MBP had no effect (12).
Although we have shown that TGF-/3-secreting CD8+ T
cells are important modulators of EAE after oral tolerization
to MBP (11), the effect of oral tolerance on the expression
of TGF-0 and other cytokines in the brain of animals with
EAE is unknown.
Materials and Methods
InductionofOral Tolerance
￿
Female Lewisrats 6-8-wk-ofage were
obtained from Harlan Sprague Dawley, Inc. (Indianapolis, IN). Prep-
aration of guinea pig MBP, immunization, scoring ofclinical dis-
ease, and induction oforal tolerance were performed as previously
described (12). Rats were fedby gastricintubation using astainless
steel feeding needle (Thomas Scientific, Swedesboro, NJ). The an-
tigens MBP and OVAwere dissolved in PBS (Gibco Laboratories,
Grand Island, NY) at 1 mg/ml and administered five times before
immunization at 2-3-d intervals. LPS (Sigma Chemical Co., St.
Louis, MO) from Escherichia coli strain 0127:138 was dissolved in
PBS at 1 mg/ml and administered alone as above at a dose of 1
mg per feed, or together with MBP.
Specimen Collection.
￿
The onset of clinical EAE was day 10-11
after immunization, and thepeak of disease was between days 14
and 15. The rats were killed at day 14, theirbrains were surgically
removed, and snap-frozen in liquid nitrogen-chilled isopentane and
stored at -80°C.
Antibodies. Murine mAbs were obtained, unless otherwise
specified, from Sera-Lab (Accurate Chemicals & Scientific Corp.,
Westbury, NY). Additional antibodies were produced in our labora-
tories or obtained from the investigators listed. This panelincluded
mAbs to all rat leukocytes (CD45, OX-1); panT marker (CD5,
OX-19); TCR-tx//3 chains (R73; courtesy of Dr. T. Hunig, Mar-
tinstried, Germany); T cell subsets (CD4, BWH4; CD8, OX-8);
mononuclear phagocytes (ED-1, ED-2); and neutrophils (RP-3;
courtesy of Dr. F. Sendo, Yamagata, Japan). Activation of
mononuclear or endothelial cells was assessed using antibodies to
class II antigens (OX-3); p-55 chain of the IL-2R(CD25, ART18;
courtesy of Dr. T Diamantstein, Berlin, Germany); intercellular
adhesion molecule-1 (ICAM-1, CD54, 1A29; courtesy of Dr. M.
Miyasaka, Tokyo, Japan); proliferating cell nuclear antigen (PCNA;
Dako Corp., Carpinteria, CA); tissue factor (Al-3) (13) andthrom-
bomodulin (TM-4; courtesy of Dr. H. Salem, Melbourne, Aus-
tralia) (14);andby labeling for thecytokines ILlei (C42, Olympus
Corp., Lake Success, NY); IL-2 (1D10) (15);11,4(Genzyme Corp.,
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Boston,MA); IL-6 (R&D, Minneapolis, MN); 11,8 (ICN Biomed-
icals, Inc., Costa Mesa, CA); IFN-y (DB-10; courtesy of Dr. P.
van der Meide, Rijswijk, Holland); TNF-cx (JD10; from Dr. I.
McKenzie, Melbourne, Australia); TGF-0 (R&D Systems, Inc.,
Minneapolis, MN); and prostaglandin-E2 (PGE2; Sigma Chemical
Co.). Rat Ig-absorbed goat anti-mouse Ig (Sigma Chemical Co.);
rabbit anti-goat Ig, and rabbit peroxidase anti-peroxidase (PAP)
(Dako Corp.) were obtained commercially. Details of the use of
these antibodies, isotype-matchedcontrol mAbs andpurified rabbit
or goat Igs in immunohistologic studies have recently been de-
scribed (16).
Immunohistology.
￿
Brainsamples (cerebrum andcerebellum) were
harvestedfrom each rat at day 14 or 18 afterdiseaseinduction (three
samples per group per time point). Tissues were frozen in liquid
nitrogen and stored at -80°C in preparation for immunohisto-
logic studies, or fixed in neutral-buffered formalin, embedded in
paraffin, andsectionedforlightmicroscopy. Cryostat sections were
fixed in paraformaldehyde-lysine-periodate fordemonstration ofleu-
kocytes and activation antigens, or in acetone for the labeling of
cytokines, and stained by a three-layer (for polyclonal antibodies)
or four-layer (for mAbs) peroxidase-antiperoxidasemethod as pre-
viously described (16).
Data Quantitation andStatistics.
￿
Quantitation ofdiscretely-labeled
leukocytes in andsurrounding cerebral andcerebellar small vessels
wasundertaken by counting the number oflabeled cells (mean ±
SD)/100nucleated cells in each of five consecutive high powerfields
(HPF, x400). This allowedcorrection forvariably sized leukocyte
collections andvessel diametersin different sections. Threerats per
treatment groupwere studied foreach marker. Statistical significance
ofdifferences betweenexperimental groups was determined by the
Student's t test; differences ofp < 0.05 were considered significant.
Cytokine and endothelial labeling of serial sections from each of
these rats wasjudged semiquantitatively because of the diffusion
ofreaction products beyond individual cells (cytokines) or because
ofextensive, oftencontinuous labeling of endothelial or meningeal
cell aggregates. Thus, as described previously (16), results ofcytokine
and endothelial labeling in 20 consecutive fields were judged as
(-) absenceoflabeling; (±)<10 cellsper section or tracelabeling;
(1+) few small foci; (2+) multiple foci; and (3+) multiple large
perivascular collections anddiffuse submeningeal staining. Evalua-
tion of the slides was performed blindly.
Results
Cellular Infiltrate and Cytokine Pattern in the Brains ofOVA-
fedAnimals. Lewis rats fed OVA developed clinical EAE at
day 10 after immunization. The incidence of the disease was
100% and the average severity at peak of disease (day 14)
was 2.8 (range 1-4), consistent with our previously reported
observations (12). Oral administration of an irrelevant an-
tigen such as OVA has no effect on EAE and served as a con-
trol for animals fed MBP. Immunohistological evaluation of
brains harvestedfrom OVA-fed animals at the peak of disease
showed dense submeningeal and perivascular infiltrates. As
shown in Table 1 andFig. 1, approximately halfoftheperivas-
cularmononuclearcells were T cells as demonstrated by posi-
tive labeling with antibodies to TCR-ot/o (Fig. 1a) whereas
the other half consisted of ED1+ macrophages (Fig. 1 c).
20-30% of the infiltrating perivascular mononuclear cells
showed evidence of activation with expression of IL2R (Fig.
1 e), Ia antigens (Fig. 1 g), and PCNA (not shown) . Cere-bral microvessels showed a similar upregulation of Ia expres-
sion . Essentially, allmononuclear cells and vascular endothelial
cells in OVA-fed animals were ICAM-1' (Fig . 1 i) . Tissue
factor procoagulant antigen expression was increased whereas
TM expression was essentially absent compared with naive
rats (data not shown) . In addition, as shown in Table 2 and
Fig . 2, staining with antibodies to cytokines revealed strongly
positive staining of mononuclear cells forIL-1 (Fig. 2 a), and
IL-6 (Table 2) . 20-30% of perivascular mononuclear cells were
labeled with IL-2 (Fig . 2 e), and a similar proportion was
IFN-,y' (Fig . 2 g) . Approximately half of the perivascular
mononuclear cells in OVA-fed animals showed labeling with
TNF-ca (Fig . 2 c) . Most vascular endothelial cells and occa-
sional mononuclear cells were labeled with IL-8 (Fig. 2 i) .
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All values represent mean number of labeled cells ± SD/100 nucleated cells in and surrounding cerebral or cerebellar small vessels, 5 HPF/rat brain
and three rats per treatment group .
"p <0.001 compared with OVA- or LPS-fed animals .
There was no detectable staining with antiTGF-(3, IL4, or
PGE (Fig . 3, a, d, and g, respectively) . As expected, there
was no detectable staining for cytokines or cellular markers
in naive animals (negative controls) .
Cellular Infiltrate and Cytokine Pattern in MBP-tolerized
Animals . As previously reported (12), the clinical expres-
sion of EAE was decreased in rats orally tolerized by MBP
before immunization, when compared with controls . The
incidence of disease was 60% and the average clinical score
at thepeak of diseasewas 1.0 . Histologically, there was inhi-
bition of inflammatory responses with only small focal leu-
kocytic infiltrates (Fig. 1, b and d) . Leukocytes lacked activa-
tion markers as evidenced by decreased staining with IL-2R
(Fig. 1j) andPCNA (not shown) . The expression of Ia and
Based on examination of 20 HPF/rat and three rats per group and graded semiquantitatively as (0) absence of labeling, (±) trace labeling, (1+)
few small foci, and (2 + ) multiple foci .
Table 1 . Perivascular Mononuclear Infiltration and Activation Markers in Brains ofEAE vs Orally Tolerized Rats
Feeding protocol
Naive OVA MBP' MBP + LPS` LPS
Leukocytes 0.8 ± 0 .5 84.8 ± 45.9 8.8 ± 6.3 6.8 ± 4.7 74.5 ± 33.5
TCR-a/(3 0.2 ± 0.4 48.2 ± 22.3 6.3 ± 4.1 4.7 ± 2.6 50.6 ± 29.5
CD4' Cells 0.5 ± 0 .4 55 .3 ± 28.3 4.6 ± 3.9 3 .8 ± 2.9 33 .2 ± 18.3
C138' Cells 0.1 ± 0 .3 15 .3 ± 11 .6 0.5 ± 0.4 0.6 ± 0.6 12.6 ± 10.1
Macrophages 0.4 ± 0 .4 43.3 ± 19.2 4.3 ± 3.9 3 .5 ± 2.8 32.8 ± 21.3
IL-2R 0.0 15 .3 ± 5.0 0.2 ± 0.2 0.0 12.8 ± 8.4
Ia 0.0 27.8 ± 14.8 2.3 ± 1 .5 1 .8 ± 1.4 28.5 ± 24.5
ICAM-1 0.0 69.2 ± 38 .4 4.8 ± 3.2 5 .4 ± 1.9 44.7 ± 23.6
Table 2 . Cytokine Expression in
Naive
the Brain at the Peak
OVA
of Disease (Day 14)
Feeding protocol
MBP MBP + LPS LPS
IL-1 0 2+ 1+ 0 2+
TNF 0 2+ 0 ± 2+
IL-2 0 2 + 1+ 0 2+
IFN-.y 0 2 + 0 0 2+
IL-6 0 2 + 0 0 2+
IL-8 0 2 + 0 0 2+
TGF-(3 0 0 2+ 2+ 0
IL-4 0 0 ± 2+ 0
PGE 0 ± 0 2+ ±Figure 1 .
￿
Paired photomicrographs of immunoperoxidase labeling of cryostat sections of cerebri from rats killed on day 14 (peak of disease) after
immunization with MBP/CFA . Panels on the left (a, c, e, g, and i) are from control rats fed OVA, and panels on the right (b, d,f h, and j) are
from rats fed MBP (hematoxylin counterstain, x400) : (a and b) TCR-a/,3+ perivascular mononuclear cells ; (c and d) ED1* (macrophages) perivas-
cular mononuclear cells ; (e andf) IL-2R+ (CD25) perivascular mononuclear cells ; (g and h) Ia' mononuclear cells ; and (i and j) ICAM-1' (CD54)
mononuclear and vascular endothelial cells.
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￿
Paired photomicrographs of immunoperoxidase labeling of cryostat sections of cerebri from rats killed on day 14 (peak of disease) after
immunization with MBP/CFA. Panels on the left (a, c, e, g and i) are from control rats fed OVA, and panels on the right (b, d,f h, andj) are from
rats fed MBP (hematoxylin counterstain, x400) : (a and b) ILl0+ perivascular mononuclear and endothelial cells ; (c and d) TNF-«+ perivascular
mononuclear cells; (e and f) IL2+ perivascular mononuclear cells ; (g and h) IFN-y+ perivascular mononuclear cells; and (i and j) IL8+ submeningeal
vascular endothelial and mononuclear cells.Figure 3 .
￿
Paired photomicrographs of immunoperoxidase labeling of cryostat sections of cerebri from rats killed on day 14 (peak of disease) after
immunization with MBP/CFA . Panels on the left (a, d, and g) are from control rats fed OVA, middle panels (b, e, and h) are from rats fed MBP,
and panels on the right (c, f, and i) are from rats fed MBP plus LPS (hematoxylin counterstain, x400) : (a, b, and c) TGF-,l3' submeningeal vascular
endothelial and mononuclear cells ; (d, e, andf) IL4+ mononuclear and vascular endothelial cells ; and (g, h, and i) PGE Z' endothelial and mononuclear
cells.
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dition, staining with antibodies to cytokines revealed absent
to weak staining with IL1 (Fig. 2 b), IL -2 (Fig. 2 .), IL6,
IL-8 (Fig. 2j), IFN -'Y (Fig . 2 h), and TNF-cx (Fig. 2 d) . How-
ever, in contrast to OVAfed animals, there was positive staining
with antiTGF-0 in MBP tolerized animals (Fig . 3 b) .
Cellular Infiltrate and Cytokine Pattern inMBPPlusLPS Toler-
ized Animals. Feeding LPS alone did not affect EAE either
clinically or immunohistologically (Table 1) . The cytokine
pattern ofstaining for IL-1, -2, -6, and -8, TNF-oz, andIFN-y
was identical in LPS-fed animals to that seen in OVA-fed
animals . However, in animals fed LPS orally in conjunction
with MBP, there was added protection clinically (incidence
20%, average score at the peak of disease 0.2), which was
consistent with our previously reported observations (12) .
Immunohistologic examination of brain sections at day 14
showed that the decrease in inflammatory response was iden-
tical to that seen in MBP-fed rats (Table 1) . The cytokine
staining pattern showed decreased labeling for IL-1, -2, -6,
and -8, TNF-cx, and IFN-y, but increased staining for TGF-,(3,
11,4, and PGE2 (Fig . 3, c, f, and i, respectively) . Thus, in
comparison with animals fed MBP alone, animals fed with
MBP plus LPS showed an increased expression of IL-4 and
PGE2 in the brain in addition to the increase in TGF-0 seen
with MBP feeding. There was normal TM expression and
no upregulation of tissue factor expression in these rats.
CytokinePattern in Brains ofOVA, MBP, andMBPplus LPS-
fed Animals after Recovery (Day 18) . In OVA-fed animals,
examination ofbrain sections taken on day 18 after immuni-
zation (corresponding with clinical recovery), showed per-
sistent submeningeal and perivascular infiltrates . Staining for
IL-2 and IFN-y was markedly diminished, but staining for
TNF-ci was still present . However, in contrast to day 14,
the leukocytic infiltrates and associated vessels werenow heavily
stained for TGF-0 and IL-4 . In MBP-fed animals on day 18,
inflammatory cells around small vessels werenow stained for
IL-4 in addition to the TGF-0 staining noted on day 14 . In
MBP plus LPS-fed animals, there was persistent staining for
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11,4, TGF-/3, and PGE . These results are summarized in
Table 3 .
Discussion
Perivascular infiltration ofmononuclear cells into the cen-
tral nervous system is a pathologic hallmark for EAE and
multiple sclerosis (17) . Consistent with previous reports (18),
our data show perivascular infiltrates consisting primarily of
C134' T cells and macrophages and increased la expression
on cerebral endothelial cells in the brains of animals with
EAE . It is unclear whether increased la expression on vas-
cular endothelial cells plays a role in the disease pathogenesis,
or whether it is a byproduct of exposure to activated T cells.
We also found evidence of activation in the perivascular
infiltrates as seen by increased expression ofIL-2R andPCNA.
Furthermore, the infiltrates stained positively for ILA and
TNF-a, which are produced by activated macrophages and
synergize with IFN-y in upregulation of class I, class II, and
ICAM-1 molecules and have potent activating effects on en-
dothelial cells (19) . The increased expression ofIL1, -2, TNF,
andIFN-y at the height of clinical disease is compatible with
findings in murine chronic relapsing EAE (CREAE) (20) and
in multiple sclerosis (MS) brains (21-23) . ILA and TNF down-
regulate TM expression on endothelial cells and stimulate
endothelial cells in vitro to secrete tissue factor (TF), causing
a conversion of the endothelial cell surface from an anti-
coagulant to a procoagulant state leading to local fibrin depo-
sition (24, 25) . Our findings of decreased TM and increased
TF expression on the surface of endothelial cells in the brains
of OVA-fed animals at the height ofdisease, provide a demon-
stration ofsuch cytokine interactions in vivo and support the
findings previously described in vitro.
Although various cells in the central nervous system are
capable of cytokine production (26), we found the expres-
sion of these cytokines to be localized around the inflamma-
tory infiltrates . This anatomic location of cytokine expres-
sion correlates with their function in cell recruitment,
Based on examination of 20 HPF/rat and three rats per group and graded semiquantitatively as (0) absence of labeling, (±) trace labeling, (1+)
few small foci, and (2 + ) multiple foci .
Table 3 . Cytokine Expression in the
Naive
Brain after Recovery (Day 18)
OVA
Feeding protocol
MBP MBP + LPS
IL-2 0 ± 0 0
TNF-cY 0 1 + 0 0
IFN--y 0 ± 0 0
TGF-0 0 2 + 2+ 2+
IL-4 0 2 + 2+ 2+
PGE2 0 ± ± 2+activation, and differentiation, and supports their role in the
pathogenesis of the disease. Recent reports on the impor-
tance ofadhesion molecules on endothelial cells for lympho-
cyte migration and homing (27, 28) suggest that vascular
endothelial cells play an active role in disease pathogenesis,
which is consistent with our finding of increased ICAM ex-
pression in the OVAfed group and decreased expression in
the MBP-fed and MBP plus LPS fed groups.
We also found increased expression ofIL-6 and 1178 in OVA
fed animals with EAE . IL-6 is produced by a variety of cells
and is a potent inducer ofB cell differentiation (29) . Increased
production of IL-6 has been reported in several autoimmune
diseases (30, 31) and has been described in EAE (32) . The
increased production ofIL-6 in EAE could explain the finding
of raised Ig levels in the CSF ofEAE animals and by analogy
in MS patients . The present report is the first demonstration
of increased IL-8 expression in animals with EAE . IL-8 stimu-
lates neutrophil chemotaxis (33) and can be secreted by acti-
vated T cells, monocytes (34), and vascular endothelial cells
(35) . The expression of IL-8 correlates well with the presence
of neutrophils in inflammatory infiltrates.
At the time of clinical recovery, OVA-fed animals showed
expression ofTGF-0 and IL-4 around the blood vessels and
mononuclear infiltrates. Biologically active TGF-0 is secreted
by antigen-activated T cells and by mononuclear phagocytes,
and is generally a negative regulator of immune responses
(36) . We have previously found that the injection of anti-
TGF-(3 serum into Lewis rats immunized with MBP/CFA
resulted in an increased severity and duration of disease, which
suggests that TGF-0 plays a role in natural recovery from
EAE (11) . Furthermore, Karpus and Swanborg (37) have iso-
lated CD4+ postrecovery cells from Lewis rats with EAE
that suppress EAE via adoptive transfer and that suppress in
vitro via the secretion of TGF-/3 . The present results are the
first demonstration that TGF-0 is expressed de novo in the
brains of recovering animals and suggest that these CD4+
postrecovery cellsmay be acting at the target organ . The rela-
tionship of these TGF-0 secreting CD4+ postrecovery cells
to TGF-0 secreting CD8+ T cells generated after oral toler-
ance remains unknown at this time. Of note is that the ad-
ministration ofexogenous TGF-0 suppresses EAE and other
experimental autoimmune diseases (38-40) .
In addition to TGF-(3, IL-4 also appeared in the inflamma-
tory infiltrates of recovering OVA-fed EAE animals. The in-
tracerebral cytokine staining patterns observed in this study
are consistent with the reported immunoregulatory effects
of IL-4 in vitro (41) . The expression of IL-4 may indicate the
presence of IL-10-producing cells. We were unable to stain
for IL-10 in the present study because of the current lack of
antibodies to rat IL-10 . Of note, is that both IL-4 and IL-10
are known to downregulate Th1 functions in mice (42, 43),
and, based upon recent reports, it is likely that Th1 and Th2
type cells exist in the rat (44, 45) . Thus, recovery from EAE
may be associated both with the activation of TGF-(3-secreting
cells and of IL-4-secreting Th2 type cells that regulate Th-1
type cells and inhibit their secretion of proinflammatory
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cytokines . Whether IL4 alone mediates the immunosuppres-
sive effect, or whether it is a marker for Th2 cells that act
through the elaboration of other immunosuppressive cytokines
such as IL-10 (42, 43), is unknown .
In MBP orally tolerized animals, we found marked inhibi-
tion of the inflammatory infiltrate, downregulation of
cytokines associated with immune activation, and upregula-
tion of TGF-/3 . Thus, IM, -2, -6, and -8, TNF-cx, and IFN-
-y expression was diminished, whereas there was prominent
staining for TGF-(3 . The presence of TGF-0 in the brains
of MBP-fed but not OVA-fed animals at the height of disease
corroborates our previous findings that oral tolerance to MBP
in the Lewis rat is actively mediated (2) . Of particular note
is that IL4 was not detected inMBP orally tolerized animals
on day 14, which suggested that suppression ofEAE induced
by MBP feeding was not merely due to the earlier activation
of natural recovery mechanisms .
In MBP plus LPS orally tolerized animals, there was an
increased expression of IL4 and PGE2 in the brain on day
14, in addition to the increase in TGF-0 expression seen in
MBP-fed animals . During the recovery phase, MBP plus
LPS-fed animals continued to show expression of PGE2 . A
regulatory role for PGs in EAE has been postulated, since
animals treated with indomethacin, an inhibitor ofPG syn-
thesis, developed a more severe form of EAE (46) and PGE2
inhibits MBP-stimulated proliferation ofMBP-sensitized lym-
phocytes in vitro (47) . In the present study, we found PGE2
to be present in the infiltrates ofMBP plus LPS-fed animals
but not in the other groups, even during recovery, which
suggests that it does not play a role in natural recovery from
EAE . Local adjuvant effects of LPS in gut-associated lym-
phoid tissue may result in the activation of PGE2 producing
regulatory cells since PGE2 was found in the brains ofMBP
plus LPS fed but not in MBP-fed animals, and since the syn-
ergistic effect of LPS on oral tolerance is seen with oral but
not with subcutaneous administration of LPS (12) .
The results we have obtained further implicate a role for
actively mediated suppression as opposed to clonal anergy
(48) after oral tolerance to MBP in the Lewis rat EAE model
and identify locally secreted TGF-0 as a mediator of our pre-
viously described bystander suppression associated with oral
tolerance (49) . The differential expression of TGF-a, IL4,
and PGE2 appear to represent different classes of im-
munoregulatory cells that participate in suppression . This is
true both for natural recovery from EAE and for orally in-
duced tolerance . The finding ofIL4 in the target organ during
natural recovery and inMBP plusLPS orally tolerized animals
implicates a Th-2 type response as participating in suppressing
inflammation . Characterization ofthe cells that secreteTGF-a,
IL4, and PGE2 and the mechanisms by which they are trig-
gered is now required . Our results suggest that active sup-
pression by inhibitory cytokines may represent an important
mechanism of tolerance maintenance in the host and have
implications for the treatment of autoimmune diseases in
humans by oral tolerance to autoantigens (50) .References
We thank Kris Betres for technical support and Maida Uhlig for help in preparing the manuscript.
This work was supportedby National Institutes of Health grantN529352, andby a grant from Autolm-
mune Inc. S. J. Khoury is a recipient of the National Multiple Sclerosis Society fellowship (1989-1991).
Address correspondence to S. Khoury, Center for Neurologic Diseases, 221 Longwood Avenue, Boston,
MA 02115.
Received for publication 7July 1992 and in revisedform 11 August 1992.
1. Mowat, A. 1987. The regulation of immune responses to di-
etary protein antigens. Immunol. Today. 8:93.
2. Lider, O., L.M.B. Santos, C.S.Y . Lee, D.J. Higgins, andH.L.
Weiner. 1989. Suppression of experimental autoimmune en-
cephalomyelitis by oral administration of myelin basicprotein
II. Suppression of disease and in vitroresponse is mediated by
CD8* T lymphocytes. J. Immunol. 142:748 .
3. Higgins, P., and H.Weiner. 1988. Suppression ofexperimental
autoimmune encephalomyelitis by oral administration of my-
elin basic protein and its fragments. J. Immunol. 140:440.
4. Brod, S.A., A.Al-Sabbagh, R.A.Sobel, D.A. Hafler, andH.L.
Weiner. 1991. Suppression of experimental autoimmune en-
cephalomyelitis by oral administration of myelin antigens IV
Suppression of chronic relapsing disease in the Lewis rat and
strain 13 guinea pig. Ann. Neural. 29:615.
5. Bitar, D., and C. Whitacre. 1988. Suppression ofexperimental
autoimmune encephalomyelitisby oral administration of my-
elin basic protein. Cell. Immunol. 112:364.
6. Nussenblatt, R., R. Caspi, R. Mahdi, C. Chan, F. Roberge,
O. Lider, and H. Weiner. 1989. Inhibition of S-antigen in-
duced experimental autoimmune uveoretinitis by oral induc-
tion of tolerance by S-antigen. J. Immunol. 144:1689.
7. Nagler-Anderson, C., A. Bober, M. Robinson, G. Siskind, and
G. Thorbecke. 1983. Suppression of type II collagen-induced
arthritis by intragastric administration of soluble type II col-
lagen. Proc Natl. Acad. Sci. USA. 83:7443.
8. Zhang, Z., C. Lee, O. Lider, andH.L. Weiner. 1990. Suppres-
sion of adjuvant arthritis by oral administration oftype II col-
lagen. J. Immunol. 145:2489.
9. Zhang, Z.J., L.E. Davidson, G. Eisenbarth, andH.L. Weiner.
1991. Suppression of diabetes in NOD mice by oral adminis-
trationof porcine insulin. Proc Natl.Acad. Sci. USA. 88:10252.
10. Sayegh, M.H., S.K. Khoury, WW Hancock, H.L. Weiner,
and C.B. Carpenter. 1992. Induction of immunity and oral
tolerance with polymorphic class II MHC allopeptides in the
rat. Proc Natl. Acad. Sci. USA. 89:7762.
11. Miller, A., O. Lider, A.B. Roberts, M.B. Sporn, and H.L.
Weiner. 1992. Suppressor T cells generated by oral toleriza-
tion to myelin basic protein suppress both in vitro andin vivo
immune responsesby the release ofTGF-/3 followingantigenic
specific triggering. Proc. Natl. Acad. Sci. USA. 89:421.
12. Khoury,S., O. Lider, A. Al-Sabbagh, andH.L. Weiner. 1990.
Suppression of experimental autoimmune encephalomyelitis by
oral administration ofmyelin basicprotein III. Synergistic effect
of lipopolysaccharide. Cell. Immunol. 131:302.
13. Hancock, WW, D. Gee, P. de Moerloose, F.R. Rickles, V .A.
Ewan, and R.C. Atkins. 1985. Immunohistological analysis
1363
￿
Khoury et al.
ofserial biopsies taken during human renalallograft rejection:
changing profile of infiltrating cells and involvement of the
coagulation system. Transplantation (Baltimore). 39:430.
14. Tsuchida, A., H. Salem, N.M. Thompson, R.C. Atkins, and
WW Hancock. 1992. Tumornecrosis factor production during
human renal allograft rejection is associated with depression
of plasma protein C andfree protein S levels and decreased in-
tragraft thrombomodulin expression. J. Exp . Med. 175:81.
15 . Hancock, WW ., TV Alberghini, and M. ChenWoan. 1989.
Production and use of neutralizing monoclonal antibodies to
rat interleukin 2. Transplant. Proc 21:994.
16. Hancock, W., M. Sayegh, T Sablinski, J. Kut, J. Kupiec-
Weglinski, and E. Milford. 1992. CD4 monoclonal antibody
therapy blocks mononuclear cell accumulation, cytokine
production, and endothelial activation within rat cardiac al-
lografts. Transplantation (Baltimore). 54:292.
17. Sriram, S., D. Solomon, R.V. Rouse, andL. Steinman. 1982.
Identification of T cell subsets and B lymphocytes in mouse
brain experimental allergic encephalomyelitis.J. Immunol. 129:
1640.
18. Sobel, R.A., B.W. Blanchette, A.K. Bhan, and R.B. Colvin.
1984. The immunopathology of experimental allergic en-
cephalomyelitis. II. Endothelial cell la increasespriorto inflam-
matory cell infiltration. J Immunol. 132:2402.
19. Pober, J.S., M.A.J. Gimbrone, R.S. Cotran, C.S. Reiss, S.J.
Burakoff,WFiers, and K.A. Ault. 1983. laexpression by vas-
cularendothelium is inducibleby activatedTcells andby human
.y interferon. J Exp . Med. 157:1339.
20. Baker, D., J.K. O'Neill, and J.L. Turk. 1991. Cytokines in
the central nervous system of mice during chronic relapsing
experimental allergic encephalomyelitis. Cell. Immunol. 134:505.
21. Hofman, F.M., R.I. van Hanwehr, C.A. Dinarello, S.B.Mizel,
D. Hinton, andJ.E. Merrill. 1986. Immunoregulatory mole-
cules and IL-2 receptors identified in multiple sclerosis brain.
J Immunol. 136:3239.
22. Hofman, F.M., D.R. Hinton, K. Johnson, andJ.E. Merrill.
1989. Tumornecrosis factor identified in multiple sclerosis brain.
J. Exp. Med. 170:607.
23. Traugott, U., andP. Lebon. 1988. Interferon-y andla antigen
are present on astrocytes in active chronic multiple sclerosis
lesions.J. Neurol. Sci. 84:257.
24. Bevilaqua, M.P., J.S. Pober, G.R. Majeau, R.S. Cotran, and
M.A. Gimbrone,Jr. 1984. Interleukin 1 (IL-1) inducesbiosyn-
thesis and cell surface expression of procoagulant activity in
human vascular endothelial cells.J. Exp. Med. 160:618.
25 . Bevilaqua, M.P., J.S. Pober, G.R. Majeau, WFiers, R.S. Co-
tran, and M.A. Gimbrone, Jr. 1986. Recombinant tumornecrosis factor induces procoagulant activity in cultured human
vascular endothelium: characterization and comparison with
the actions ofinterleukin 1. Proc Natl. Acad. Sci . USA . 83:4533 .
26 . Frei,K ., UV Malipiero, TP . Leist, R.M. Zinkernagel,M.E .
Schwab, andA. Fontana. 1989 . On the cellular source and func-
tion of interleukin 6 produced in the central nervous system
in viral diseases . Eur .J. Immunol. 19:689 .
27 . Yednok,TA .,C. Cannon, L.C. Fritz, F . Sanchez-Madrid, L.
Steinman, andN. Karin . 1992. Prevention ofexperimental au-
toimmune encephalomyelitisby antibodies against tx4(dl inte-
grin . Nature (Lond.). 356:63 .
28 . Zimmerman, G.A., S.M . Prescott, andTM . McIntyre . 1992 .
Endothelial cell interactions with granulocytes : tetheringand
signaling molecules . Immunol. Today. 13:93 .
29 . Hirano, T, S . Akira, T . Taga, and T. Kishimoto . 1990 . Bio-
logical and clinical aspects of interleukin 6 . Immunol. Today.
11:443 .
30 . Houssiau,F.A ., J.-P. Devogel,J . Van Damme, C.N . De Deux-
chaines, and J. VanSnick . 1988 . Interleukin-6 in synovial fluid
and serum of patients with rheumatoid arthritis and other
inflammatory arthritides . Arthritis Rheum. 31:784 .
31 . Linker-Israeli,M.,R.J. Deans, D.J . Wallace, J . Prehn,TOzeri-
Chen, and J.R. Klinenberg. 1991 . Elevated levels of IL-6 in
systemic lupus erythematosus . A putative role in pathogen-
esis .J . Immunol. 147 :117 .
32 . Gijbels, K., J . Van Damme, P. Proost,W Put, H. Carton,
andA. Billiau. 1990 . Interleukin 6 production in the central
nervous system during experimental autoimmune encephalo-
myelitis. Eur . J . Immunol. 20:233 .
33 . Yoshimura, T, K. Matsushima, S. Tanaka, E.A . Robinson,
E. Appella, J.J . Oppenheim, and E.J . Leonard . 1987 . Puri-
fication of a humanmonocyte-derived neutrophil chemotactic
factor that has sequence similarity to other defense cytokines .
Proc. Nad. Acad. Sci. USA . 84:9233.
34 . Walz, A., P . Peveri, H. Aschauer, andM. Baggiolini. 1987 .
Purification and amino acid sequencing of NAF, a novel
neutrophil-activating factor produced by monocytes . Biochem .
Biophys. Res. Commun . 149:755 .
35 . Strieter,R.M., S.L . Kunkel,H.J . Schowell,G.D . Remick, S.H .
Phan, P.A. Ward, andR.M . Marks . 1989 . Endothelial cell gene
expression of a neutrophil chemotactic factor by TNF, IL 1,
and LPS . Science (Wash . DC). 243:1601 .
36 . Roberts,A.B.,K.C . Flanders, P . Kondaiah, N.L . Thompson,
E. Van Obberghen-Schilling, L.M . Wakefield, P . Rossi, B. De
Crombrugghe,U . Heine, andM.B. Sporn . 1988 . Transforming
growth factor-/3: biochemistry and roles in embryogenesis,
tissue repair and remodeling, and carcinogenesis . Rec. Prog.
Horm. Res . 44:157 .
37 . Karpus,W ., andR. Swanborg. 1991 . CD4' suppressor cells
inhibit the function of effector cells of experimental autoim-
1364 Oral Tolerance and Brain Cytokine Expression in EAE
mune encephalomyelitis through amechanisminvolving trans-
forming growth factor beta . J . Immunol. 146:1163 .
38 . Johns, L .,K. Flanders, G. Ranges, and S . Sriram . 1991 . Suc-
cessful treatment of experimental allergic encephalomyelitis
with transforming growth factor-01 . J . Immunol. 147:1792 .
39 . Kuruvilla, A.P.,R. Shah,G.M. Hochwald,H.D . Liggitt,M.A.
Palladino, andG.J . Thorbecke. 1991 . Protective effect oftrans-
forming growth factor /31 on experimental autoimmune dis-
eases in mice . Proc. Natl. Acad. Sci. USA . 88:2918.
40 . Racke, M.K ., S . Dhib-Jalbut, P.S. Cannella, P.S . Albert, and
D.E . McFarlin . 1991 . Prevention and treatment of chronic
relapsing experimental allergic encephalomyelitis by trans-
forming growth factor-/31 . J . Immunol. 146:3012 .
41 . Paul,WW. 1991 . Interleukin-4 : a prototypic immunoregula-
tory lymphokine. Blood. 77:1859 .
42 . Mosmann, TR.,H. Cherwinski,M.W. Bond,M.A . Giedlin,
andR.L . Coffman . 1986 . Two types of murine helper T cell
clone. I. Definition according to profiles of lymphokine ac-
tivities and secreted proteins . J . Immunol. 136:2348 .
43 . Cherwinski,H.M ., J .H. Schumacher, K.D . Brown, andK.D .
Mosmann . 1987 . Two types of mouse helperT cell clone. III .
Further differences in lymphokine synthesisbetween Thl and
Th2 clones revealed by RNA hybridization, functionally
monospecific bioassays, andmonoclonal antibodies .J . Exp . Med.
166:1229 .
44 . Hancock, WW., M.H . Sayegh, C.A . Kwok, H.L . Weiner,
and C.B . Carpenter . 1992 . Oral but not intravenous alloan-
tigen prevents accelerated allograft rejection by selective in-
tragraft Th2 cell activation . Transplantation (Baltimore). In press .
45 . Papp, I .,K.J . Wieder, T. Sablinski, P.J . O'Connell, E.L . Mil-
ford, TB. Strom, andJW . Kupiec-Weglinski . 1992 . Evidence
for functional heterogeneity of rat CD4' T cells in vivo .
Differential expression of IL-2 and IL-4 mRNA in recipients
of cardiac allografts. J . Immunol. 148:1308 .
46 . Ovadia, H ., and P.Y Paterson . 1982 . Effect of indomethacin
treatment upon actively-induced and transferred experimental
allergic encephalomyelitis (EAE) in Lewis rat . Clin. Exp. Im-
munol. 49 :386 .
47 . Mannie,M.D., L. Pope, and P.Y Paterson . 1989 . Indometh-
acin augments in vitro proliferative responses ofLewis ratlym-
phocytes to myelin basic protein . Cell. Immunol. 121:196 .
48 . Whitacre, C.C ., I.E . Gienapp, C.G. Orosz, andD.M . Bitar.
1991 . Oral tolerance in experimental autoimmune encephalo-
myelitis. III . Evidence for clonal anergy.J. Immunol. 147:2155 .
49 . Miller,A., O . Lider, andH.L . Weiner. 1991 . Antigen-driven
bystander suppression following oral administration of antigens .
J . Exp. Med. 174:791 .
50 . Marx,J . 1991 . Testing of autoimmune therapy begins. Science
(Wash . DC). 252:27 .